Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Study Shows Active Ingredient in Solace PS128 Daily Probiotic Supplement Improved Motor Score and Quality of Life of Parkinson's Disease Patients

Clinical trial concludes that PS128, the active ingredient in Solace PS128, a daily probiotic supplement, improved the Unified Parkinson's Disease Rating Scale (UPDRS) and quality of life of Parkinson's disease patients.


News provided by

Solace

Nov 08, 2021, 08:00 ET

Share this article

Share toX

Share this article

Share toX

solaceprobiotic.com
solaceprobiotic.com

FREMONT, Calif., Nov. 8, 2021 /PRNewswire-PRWeb/ -- New study findings show that PS128, the active ingredient in Solace PS128, a daily gut-brain probiotic, improved the Unified Parkinson's Disease Rating Scale (UPDRS) and the quality of life of Parkinson's disease patients.

The clinical study, published by Frontiers in Nutrition, demonstrated that "PS128 supplementation for 12 weeks with constant anti-parkinsonian medication improved the Unified Parkinson's Disease Rating Scale (UPDRS) motor score and quality of life of Parkinson's disease patients."

"Clinical studies have shown potential benefits not only for Parkinson's disease, but also for clinical depression, anxiety and children with autism,” said David Lee, president of Oryx Biomedical.

Post this

The authors of the study suggest "PS128 could serve as a therapeutic adjuvant for the treatment of Parkinson's disease. In the future, placebo-controlled studies are needed to further support the efficacy of PS128 supplementation."

Solace PS128, sold by Oryx Biomedical, is a potent gut-brain probiotic available to the U.S. market. Solace is the only single-strain PS128 product in the United States.

Lactobacillus plantarum PS128, the potent beneficial bacteria found in Solace, is a naturally derived and scientifically tested daily probiotic supplement that supports the digestive and immune systems. Lactobacillus plantarum PS128 has self-affirmed USA FDA Generally Recognized as Safe (GRAS) status. As a gut-brain probiotic, Solace PS128 also has positive mental benefits and promotes a balanced, healthy mood. Each capsule of Solace contains approximately 30 billion CFUs of the highly researched PS128 strain.

"It is exciting that there is so much scientific research being conducted on PS128," said David Lee, president of Oryx Biomedical. "The active ingredient in Solace PS128 is backed by real science. Clinical studies have shown potential benefits not only for Parkinson's disease, but also for clinical depression, anxiety and children with autism."

Currently, the most common Parkinson's medication is levodopa, which replenishes dopamine. However, its effectiveness decreases over time. PS128 may help compensate for this decrease by ameliorating akinesia. Reversing akinesia, the loss of motor control, for people with Parkinson's can be life-changing, as akinesia impacts nearly all daily activities.

Such symptoms of Parkinson's disease may be caused by a neuroinflammatory molecule known as MPO. Studies have shown MPO levels dropped after PS128 administration, resulting in marked improvement in total score, mobility, activities of daily living, stigma, and cognition. PS128's potential to attenuate Parkinson's disease symptoms is leading to additional clinical trials.

PS128 was isolated by Bened Biomedical Co., Ltd. The powerful gut-brain strain in Solace PS128 has been the focus of multiple research and clinical studies by scientist and professor Ying-Chieh Tsai, chief founder of Bened Biomedical. Research is currently being conducted on the benefits of Lactobacillus plantarum PS128 on: Movement disorders, Major depressive disorder and Parkinson's disease.     

Previous research and clinical studies of PS128 have shown its positive effects on stress and anxiety, insomnia, and autism spectrum disorder. Patents of PS128 have been awarded in the United States, European Union, Japan, Taiwan, and Korea.

The strain Lactobacillus plantarum PS128 was isolated after a rigorous screening process of nearly one thousand strains of bacteria. This strain was tested for potency, effectiveness, and the ability to affect mental wellness. PS128 is a natural bacteria extracted from Brassica juncea, commonly known as brown mustard.

PS128 was proven to strengthen the immune and digestive systems, as well as improve mental health by modulating stress, reducing anxiety, and promoting a balanced mood. PS128 was named the Probiotic Product of the Year Winner at the 2018 NutraIngredients-Asia Awards.

"Solace PS128 is a healthy, safe and natural way to improve mental wellness and overall health," said Lee. "Solace PS128 is the result of more than 20 years of scientific research. We are excited to make this probiotic available and see the positive impact it will have on the mental wellbeing and health of people across the United States."

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

ABOUT SOLACE
Solace is a daily probiotic supplement that helps support the digestive and immune systems by enhancing beneficial bacteria. As a gut-brain probiotic, Solace PS128 has positive mental benefits and promotes a balanced, healthy mood. Lactobacillus plantarum PS128, the remarkably potent single-strain of beneficial bacteria found in Solace, is naturally derived and scientifically tested. Current research is examining the effects of PS128 on Parkinson's disease, clinical depression, anxiety, and children with autism. For more information, visit solaceprobiotic.com.

ABOUT PROFESSOR YING-CHIEH TSAI
Professor Ying-Chieh Tsai is the senior author of "The Add-On Effect of Lactobacillus plantarum PS128 in Patients With Parkinson's Disease: A Pilot Study." He has 30+ years researching fermentation and the microbiome and developing functional probiotics.

Media Contact

Stephanie Richards, SowGrow Public Relations, +1 6787447690, [email protected]

SOURCE Solace

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.